The same authors showed that tesevatinib efficacy in EGFR-amplified patient-derived xenograft GBM models is higher in vitro than in vivo, despite a significant distribution in the brain with respect to the plasma, probably because of drug-tissue binding and compensatory signaling [191]. The gene discussed is EGFR; the disease is glioblastoma.